Important Information for Investors: Pacira BioSciences, Inc. Securities Class Action Lawsuit
New York, NY and New Orleans, LA – Kahn Swick & Foti, LLC (“KSF”) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”).
Background on the Lawsuit
The lawsuit alleges that Pacira BioSciences, Inc. and certain of its executives made false and misleading statements and failed to disclose material information during the Class Period. Specifically, the Company is accused of downplaying the risks associated with its EXPAREL product, a non-opioid pain management system, and its commercial prospects.
Impact on Individual Investors
If you purchased Pacira BioSciences, Inc. securities during the Class Period and have suffered a financial loss, you may be eligible to recover your loss by serving as a lead plaintiff in this class action lawsuit. As a lead plaintiff, you would be entitled to certain rights and benefits, including a seat at the table in negotiations with the Company’s management and counsel, and the ability to participate in key decisions regarding the direction of the litigation.
Impact on the Business World
The securities class action lawsuit against Pacira BioSciences, Inc. is significant for several reasons. Firstly, it highlights the importance of transparency and honesty in corporate communications. Companies have a responsibility to provide accurate and timely information to their investors, and failure to do so can result in serious consequences. Secondly, it serves as a reminder that the securities laws are in place to protect investors from fraudulent and misleading conduct. Lastly, it demonstrates the role that private litigation can play in holding companies accountable for their actions and seeking justice for affected investors.
Conclusion
If you purchased Pacira BioSciences, Inc. securities during the Class Period and believe you have been negatively impacted by the Company’s alleged misrepresentations, you may be entitled to recover your losses. KSF encourages you to contact the firm as soon as possible to discuss your legal rights and options. Contact KSF at 1-877-515-1850 or via email at [email protected] to learn more about the class action lawsuit and how you may be able to participate.
- Investors have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc.
- The lawsuit alleges that the Company made false and misleading statements and failed to disclose material information during the Class Period.
- Individual investors who purchased Pacira BioSciences, Inc. securities during the Class Period may be eligible to recover their losses by serving as a lead plaintiff in the class action lawsuit.
- The lawsuit serves as a reminder of the importance of transparency and honesty in corporate communications and the role of securities laws in protecting investors.
